Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

HHS - 73655 - Interagency Pain Research Coordinating Committee - Statutory (Congress Created)


Committee NameInteragency Pain Research Coordinating CommitteeAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number73655
Original Establishment Date7/8/2010Committee StatusChartered
Actual Termination Date Committee URL
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*19
Current Charter Date7/8/2020Designated Fed Officer Position Title*Health Science Policy Advisor
Date Of Renewal Charter7/8/2022Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Linda
Exempt From Renewal*NoDesignated Federal Officer Middle NameL.
Specific Termination AuthorityDesignated Federal Officer Last Name*Porter
Establishment Authority*Statutory (Congress Created)Designated Federal Officer SuffixPhD
Specific Establishment Authority*42 USC 284Designated Federal Officer Phone*301-451-4460
Effective Date Of Authority*1/1/2010Designated Federal Officer Fax*301-402-2060
Exempt From EO 13875 Discretionary CmteNot ApplicableDesignated Federal Officer Email*
Committee Type*Continuing
Committee Function*Scientific Technical Program Advisory Board


Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Interagency Pain Research Coordinating Committee accomplishes its purpose by meeting regularly to coordinate all pain research efforts within HHS and across other relevant Federal Agencies. These meetings have resulted in recommendations to ensure no unnecessary duplication of effort, to identify critical gaps in knowledge, to disseminate information, and develop strategies for pain prevention, treatment, management, education, and research. The Committee also establishes expert work groups to address IPRCC goals and objectives. One set of work groups, including approximately 60 experts, completed and released the Federal Pain Research Pain Strategy. Many of the research priorities recommended in this strategy are being developed as initiatives to enhance the federal pain research agenda to address the opioid crisis.
How is membership balanced?*The Committee is composed of not more than 7 voting Federal representatives from agencies that conduct pain care research and treatment and 12 non-Federal voting members. The 12 non-Federal members include (a) 6 non-Federal members from among scientists, physicians, and other health professionals and (b) 6 non-Federal members from members of the general public who are representatives of leading research, advocacy, and service organizations for individuals with pain-related conditions.
How frequent & relevant are cmte mtgs?*The committee met twice in this reporting period.
Why advice can't be obtained elsewhere?*The composition of the committee provides a unique balance of expertise and opinions that cannot be obtained totally from federal staff across multiple agencies or on an ad hoc basis because of the diversity in scientific and non-scientific viewpoints needed, the importance of non-federal perspectives, and the need for continuity as the Committee considers issues over time.
Why close or partially close meetings?N/A
Recommendation RemarksBased on the assignment of duties, the Designated Federal Official and the committee decision maker positions are both held by Dr. Linda Porter.

Administrative Extensions: Drs. Buckenmaier, Carr, Clark, Helmick, Koroshetz, Kerns, Mr. Carter, Ms. Herman, and Ms. Hammitt were administratively extended while new nominees are being reviewed for this year's IPRCC nomination slate. Term end dates were updated to reflect the admin extensions. Jan Chambers end date was updated. She was administratively extended until 11/30/2019 for FY20. Her administrative extension was ended early when replacement member was appointed. Term has been updated.

Members: Dr. Martha Somerman's term date was updated. She retired from NIH and the committee on 12/31/2019. Dr. Sharon Hertz's end date was updated as she retired from her position at FDA, which ended her term on the committee. Dr. Chester Buckenmaier's start date was not accurate on last year's report - a slight typo, the date was off by 2 days. It was updated for FY 2020.

Members Fillingim, Pasternak and Underwood were serving on administrative extensions until their replacements were appointed. The reported dates on last year’s report were the full extension, but those extended terms ended early as the new 2020 members were appointed and the end dates are less than reported last year.

Daily salary costs have been estimated for Federal members of this committee. The dollar figure represents a portion of their annual salary. No funds have been transferred between the committee and the agency. No additional funds are paid to Federal employees due to membership on this committee.

Note: The COVID-19 pandemic started in March 2020, which required that the June IPRCC meeting be held virtually in this fiscal year. Virtual meetings will continue into FY 2021 indefinitely due to the pandemic.


Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*No
Outcome Trust In GovernmentNoAction Reallocate ResourcesNo
Outcome Major Policy ChangesNoAction Issued New RegulationsNo
Outcome Advance In Scientific ResearchYesAction Proposed LegislationNo
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryYesAction OtherYes
Outcome Increased Customer SatisfactionNoAction CommentNIH had led this effort to collect, collate, and publicly convey major advances in pain research over the past three years. Summaries of major advances have been posted to the website. NIH, with the oversight of the committee, developed and maintains annually a database on all federal pain research. Grants and contracts support the objectives of the National Pain Strategy. These projects are ongoing. NIH led the effort to develop a long-term strategic plan to advance pain research. The report was released in October 2017 and is in use to guide new initiatives on pain research including many to address the opioid crisis.
Outcome Implement Laws/Reg RequirementsNoGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentThe committee's mission includes making recommendations to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort and making recommendations on how to expand partnerships between public entities and private entitites to expand collaborative, cross-cutting research.Grants Review CommentNA
Number Of Recommendations*8Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe committee did not produce any new recommendations.. The SUPPORT Act expanded the scope of the IPRCC as to the research gap areas that the committee needs to address and reporting on science advances.Access Agency WebsiteYes
% of Recs Fully Implemented*75.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentN/AAccess GSA FACA WebsiteYes
% of Recs Partially Implemented*25.00%Access PublicationsNo
% of Recs Partially Implemented CommentScience advances are reported annually. The National Pain Strategy implementation is expected to take five years. The Federal Pain Research Strategy priority research areas benchmark currently are being reviewed. Updates on priority research areas identified by the Federal Pain Research Strategy are provided regularly to the IPRCC and NIH. Many priority research areas were funded by the NIH HEAL initiative.Access OtherNo
Agency Feedback*YesAccess CommentInformation on the IPRCC may be obtained from Dr. Linda Porter at or from the website:
Agency Feedback Comment*The committee receives feedback through minutes and reports presented at meetings. The IPRCC Federal Designated Official has provided updates on IPRCC activities related to relevant legislation (e.g. SUPPORT ACT) to federal agencies and congressional staff as appropriate. The IPRCC also receives feedback from federal agencies on relevant activities as mandated in the ACA and SUPPORT ACT through their regularly held meetings.Narrative Description*As specified in Public Law 111-148 (“Patient Protection and Affordable Care Act”) and amended in H.R. 6, (“Support for Patients and Communities Act”) the Committee will: (A) develop a summary of advances in pain care research supported or conducted by the Federal agencies relevant to the diagnosis, prevention, treatment, and management of pain and diseases and disorders associated with pain, including information on best practices for the utilization of non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; (B) identify critical gaps in basic and clinical research on the symptoms and causes of pain, including the identification of relevant biomarkers and screening models and the epidemiology of acute and chronic pain; the diagnosis, prevention, treatment, and management of acute and chronic pain, including with respect to non-pharmacologic treatments, non-addictive medical products, and other drugs or devices approved or cleared by the Food and Drug Administration; and risk factors for, and early warning signs of, substance use disorders in populations with acute and chronic pain; (C) make recommendations to the Director of NIH to ensure that the activities of the National Institutes of Health and other Federal agencies are free of unnecessary duplication of effort; on how best to disseminate information on pain care and epidemiological data related to acute and chronic pain; and on how to expand partnerships between public entities and private entities to expand collaborative, cross-cutting research.
Hide Section - COSTS


Payments to Non-Federal Members*$5,200.00Est Payments to Non-Fed Members Next FY*$5,200.00
Payments to Federal Members*$12,439.00Est. Payments to Fed Members Next FY*$12,439.00
Payments to Federal Staff*$168,296.00Estimated Payments to Federal Staff*$172,672.00
Payments to Consultants*$1,600.00Est. Payments to Consultants Next FY*$1,600.00
Travel Reimb. For Non-Federal Members*$8,005.00Est Travel Reimb Non-Fed Members nextFY*$8,052.00
Travel Reimb. For Federal Members*$2,205.00Est Travel Reimb For Fed Members*$2,220.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$6,006.00Est Travel Reimb to Consultants Next FY*$6,058.00
Other Costs$6,463.00Est. Other Costs Next FY*$6,528.00
Total Costs$210,214.00Est. Total Next FY*$214,769.00
Federal Staff Support (FTE)*1.10Est. Fed Staff Support Next FY*1.10
Cost RemarksThe COVID-19 pandemic started in March 2020, which reduced some costs due to the June IPRCC meeting be held virtually for this fiscal year.Est Cost RemarksNote: Due to the COVID-19 pandemic, virtual meetings will continue into FY 2021 indefinitely. If this changes, actual costs may change.
Hide Section - Interest Areas

Interest Areas

Health Care
Public Health


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-036475Interagency Pain Research Coordinating Committee2019
 COM-034674Interagency Pain Research Coordinating Committee2018
 COM-001892Interagency Pain Research Coordinating Committee2017
 COM-002247Interagency Pain Research Coordinating Committee2016
 COM-003998Interagency Pain Research Coordinating Committee2015
 COM-004362Interagency Pain Research Coordinating Committee2014
 COM-006088Interagency Pain Research Coordinating Committee2013
 COM-006572Interagency Pain Research Coordinating Committee2012
 COM-007976Interagency Pain Research Coordinating Committee2011
 COM-008660Interagency Pain Research Coordinating Committee2010